IZannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent
J, Pocock SJ, Pitt B; EMPHASIS-HF Study Group.
Eplerenone in patients with systolic heart failure and mild symptoms.
N Engl J Med. 2011 Jan 6;364(1):11-21. Epub 2010 Nov 14.
PubMed PMID: 21073363.
カテゴリー: 予防 研究デザイン: ランダム化比較試験 資金源: Supported by Pfizer. 利益相反: Dr. Zannad reports receiving fees for serving on the board of Boston Scientific,
consulting fees from Novartis, Takeda, Astra-Zeneca, Boehringer Ingelheim,
GE Healthcare, Relypsa, Servier, Boston Scientific, Bayer, Johnson &
Johnson, and Resmed, and speaker’s fees from Pfizer and AstraZeneca and
that his institution receives grant support from BG Medicine and Roche
Diagnostics on his behalf. Dr. McMurray reports receiving grant support
from the Eugene Braunwald Endowment for the Advancement of Cardiovascular
Discovery and Care. Dr. Krum reports receiving travel reimbursements from
Pfizer. Mr. Shi and Dr. Vincent report being employees of Pfizer and receiving
stock options and travel reimbursements from Pfizer. Dr. Pocock reports
receiving consulting fees from Servier, Amgen, AstraZeneca, and Novartis
and that his institution receives grants from Servier and AstraZeneca on
his behalf. Dr. Pitt reports receiving fees for serving on the board of
Novartis, consulting fees from Takeda, AstraZeneca, Boehringer Ingelheim,
GE Healthcare, Relypsa, BG Medicine, Nile Therapeutics, Merck, Forest Laboratories,
and Novartis, grant support from Forest Laboratories and Novartis, and
stock options from Relypsa, BG Medicine, Nile Therapeutics, and Aurasenc
and that his institution receives grant support from Forest Laboratories
on his behalf and he and his institution receive grant support from Bayer.
No other potential conflict of interest relevant to this article was reported.